Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Atletico Madrid

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

- PMLiVE

UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa

The drug was associated with sustained improvements in the signs and symptoms of the inflammatory skin disease

- PMLiVE

Innovating medical education to deliver 21st century healthcare

Technological advancements are reshaping the healthcare industry. Onyx Health's Medical Education Lead, Sarah Seilly, discusses the innovative techniques at the forefront of enhancing patient care.

Onyx Health

- PMLiVE

MHRA approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

Kristin Ludwig joins BOLDSCIENCE’s leadership team as SVP to lead new BOLDADVOCACY division

BOLDADVOCACY expands BOLDSCIENCE’s strategic medical communications services into patient advocacy and engagement

BOLDSCIENCE

Healthcare professionals seek independent medical education (IME)

The evolving healthcare advertising landscape

Industry experts share their insights on the emerging trends in healthcare advertising

Wiley

- PMLiVE

UCB presents positive phase 3 results for bimekizumab in hidradenitis suppurativa

The skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Avalere Health

We are EatMoreFruit

Welcome to EatMoreFruit - We are a London-based top 10 independent healthcare communications agency. PR, digital, creative & commercial strategies for innovators in health, pharma and wellbeing.

EatMoreFruit

- PMLiVE

MHRA approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

EU flag

EC approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links